Chelsea Football Club Select World-Class Technology Partner FPT to Drive Global Transformation
10.4.2025 08:00:00 CEST | Business Wire | Press Release
Chelsea Football Club is excited to announce an innovative global partnership with FPT Corporation (FPT), Vietnam’s most successful technology solutions provider, who specialise in supporting the digital transformation journeys of several of the world's largest organisations with AI-enabled services and solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250409141532/en/
Founded in 1988, FPT has driven Vietnam’s technology surge over the last three decades. The market-leader will bring its future-ready technology and industry-leading workforce to advance Chelsea FC’s digital capabilities with aligned values of teamwork, ambition and hard work, enabling the club to transform and accelerate performance and deliver richer experiences for the club’s fans at home and abroad.
With FPT’s expertise in digital technology, software development, product engineering and IT service management, Chelsea FC will closely collaborate with FPT’s team of experts to identify and develop solutions that support the club’s global growth ambitions.
Chelsea FC and FPT share a bold vision to transform how the Blues engage and interact with their ever-growing global fan base, enriching the fan experience not only at the stadium but also across diverse digital channels, wherever they are. This partnership unlocks boundless opportunities to innovate - leveraging technology to inspire current and future generations and deepen their connection to the club like never before.
Todd Kline, President of Commercial for Chelsea Football Club, said: "As Chelsea FC celebrates its 120th anniversary, we know our future will be shaped not only by our commitment to success on the pitch but by the transformation of our club using technology. Vietnam has experienced significant growth in recent years and emerged as a global digital hub, thanks to the energy and spirit of its people. FPT’s expertise in core business systems, data intelligence, and AI makes them the perfect partner to propel Chelsea FC into this new era.”
Pham Minh Tuan, FPT Software CEO and Executive Vice President, FPT Corporation said: "Becoming an Official Partner of Chelsea FC marks an exciting chapter in FPT’s global expansion. This partnership not only reflects our shared commitment to excellence but also showcases the transformative power of technology in enhancing performance and creating unforgettable experiences. At FPT, our vision is to bring happiness and meaningful connections to our customers and communities; and we look forward to partnering with one of the world’s top football clubs to continue making this vision a reality.”
“Our unwavering commitment to the UK market drives us to implement cutting-edge innovations, including data analytics and artificial intelligence, that will benefit Chelsea FC, its fans, and the broader community,” stated Mark Scrivens, FPT Software United Kingdom CEO, FPT Corporation. “By leveraging these technologies, we aim to enhance on-field performance, deliver a personalised and immersive Chelsea FC experience, and foster a stronger, more connected community off the pitch.”
About Chelsea Football Club
Chelsea Football Club is one of the top football clubs globally and its men’s team were the FIFA Club World Cup winners for 2021, with the final when the side beat Brazilian side Palmeiras in Abu Dhabi held in 2022 due to the pandemic. That success followed winning the UEFA Champions League for a second time in 2021 with victory over Manchester City in Porto.
Founded in 1905, Chelsea is London’s most central football club, based at the iconic 40,000-capacity Stamford Bridge stadium. Nicknamed ‘The Blues’, the club lifted the Champions League for the first time in 2012 and has also won the Premier League five times, the FA Cup eight times, the Football League Cup five times, the UEFA Europa League twice, the UEFA Cup Winners’ Cup twice, the UEFA Super Cup twice and the Football League Championship once, in 1955.
The 2021 Champions League and Super Cup triumphs ensured Chelsea became the first club to win four major UEFA club competitions twice, following its earlier successes in those two competitions as well as the Europa League and Cup Winners’ Cup.
The Chelsea Women’s team have enjoyed a huge amount of success and in 2024 won the FA Women’s Super League for a fifth consecutive year and the seventh time overall. The Women’s FA Cup has been won on five occasions. The side has also captured the FA Women’s League Cup three times as well as reaching the UEFA Women’s Champions League final in 2021.
In addition to possessing some of the world’s most recognisable players, Chelsea has also invested in its future with a state-of-the-art Academy and training centre in Cobham, Surrey. Since the Academy building’s opening in 2008, the club has won seven FA Youth Cups, back-to-back UEFA Youth League titles in 2015 and 2016, and the U23 and U18 Premier League national championships most recently in 2019/20 and 2017/18 respectively.
The Chelsea Foundation boasts one of the most extensive community initiatives in sport, helping to improve the lives of children and young people all over the world.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organisations worldwide. Committed to elevating Vietnam’s position on the global tech map and delivering world-class solutions for global enterprises, the Corporation focuses on five strategic areas: Artificial Intelligence, Automotive, Semiconductor, Digital Transformation, and Green Transformation. In 2024, FPT reported a total revenue of USD 2.47 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT's global IT services, please visit https://fptsoftware.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409141532/en/
Contacts
Media
Mai Duong (Ms.)
FPT Corporation
FPT Software PR Manager
MCP.PR@fpt.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom